

## [Nifedipine](#)

Not recommended as an essential medicine

Section:

[12. Cardiovascular medicines](#) [12.3. Antihypertensive medicines](#)

Codes ATC: [C08CA05](#)

Indication

Essential hypertension Code ICD11: [BA00.Z](#)

INN

Nifedipine

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

**Oral > Solid:** 10 mg tablet ; sustained-release formulations

Historique des statuts LME

Ajouté pour la première fois en 1987 ([TRS 770](#))

Modifié en 1997 ([TRS 882](#))

Retiré en 2005 ([TRS 933](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

Des médicaments appartenant à la même classe pharmacologique peuvent être utilisés

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Nifedipine](#)

DrugBank

[Nifedipine](#)

Résumé des preuves et recommandation du comité d'experts



During its meeting in 2003, the Committee recommended that long-acting nifedipine be reviewed for possible fast-track deletion at the meeting in 2005. A review was prepared by the WHO Collaborating Centre for Research and Training in Pharmaco-epidemiology in Barcelona, Spain, and comments were received from Médecins Sans Frontières. The Committee noted that the presentation of nifedipine in the 13th Model List was slightly ambiguous and confirmed that only slow-release tablets of 10 mg were listed. The Committee also noted that short-acting nifedipine is not recommended in the treatment of hypertension due to its relative lack of safety when compared with other antihypertensive medicines. The review prepared by the Collaborating Centre identified that the clinical trial evidence showing benefits of dihydropyridine calcium-channel blockers was strongest for amlodipine. On the basis of the review, the Committee recommended that sustained-release nifedipine be replaced with amlodipine (5 mg tablet) with a square box as the representative long-acting dihydropyridine calcium channel blocker. The Committee also recommended a review of the continued use of the square box at its next meeting.